TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10811855

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 0
Study: 8636652

Group type: EXPERIMENTAL
Intervention: L-glutamine, 4 gm swish and swallow twice a day, from day 1 of chemotherapy for 28 days or for 4 days past the resolution of any post-chemotherapy mucositis
Number of subjects: 14
Study: 1558421

Group type: COMPARATOR
Intervention: RYGB-1 (defunctionalized jejunum 75 cm)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RYGB-2 (defunctionalized jejunum 150 cm)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both RYGB-1 and RYGB-2
Number of subjects: 45
Study: 4018423

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unchanged conventional treatment (UCT)
Number of subjects: 30
Study: 30500939

Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccination (PPV)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccination (PPV) with SART2‐93 selection
Number of subjects: 88
Study: 28958324

Group type: EXPERIMENTAL
Intervention: Self-reported exercise (measured in metabolic equivalents of task hours/week)
Number of subjects: 15486
Study: 25424601

Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD; containing 500 IU/250 ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plain doogh (PD; containing 150 mg calcium and no vitamin D/250 ml)
Number of subjects: 100
Study: 23627921

Group type: EXPERIMENTAL
Intervention: Dry-stored dialyzer with low blood level in the venous chamber (DL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dry-stored dialyzer with high blood level in the venous chamber (DH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wet-stored dialyzer with high blood level (WH)
Number of subjects: 20
Study: 21140164

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 1 mg/day for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20201179

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16966313

Group type: EXPERIMENTAL
Intervention: Manual Muscle Test (MMT) using a 0 to 10-point scale for intra-rater reliability
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Manual Muscle Test (MMT) using a 0 to 10-point scale for inter-rater reliability
Number of subjects: 19
Study: 16137053

Group type: EXPERIMENTAL
Intervention: Group A (TV = 7 ml/kg, f=12 bpm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (TV=5 ml/kg, f=15 bpm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group C (TV=7 ml/kg, f=15 bpm)
Number of subjects: 30
Study: 10895409

Group type: EXPERIMENTAL
Intervention: Adenosine (20 mg/10 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 20
Study: 9090646

Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy (ISG) with anti-225.28S
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 36
Study: 8222787

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 50, 100, 200, and 400 micrograms twice daily
Number of subjects: 672

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 200 micrograms twice daily
Number of subjects: 672
Study: 3513105

Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate (BDP) for 2 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (Salbutamol)
Number of subjects: 9
Study: 31752498

Group type: EXPERIMENTAL
Intervention: Dosing practices based on current recommendations (46%-76% adherence)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Lean body weight for dosing propofol, non-depolarising muscle relaxants, sugammadex, and opioids
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Total body weight for dosing suxamethonium
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Use of resources to assist dosing practices in obesity
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Increased incidences of adverse events related to drug dosing
Number of subjects: 230
Study: 29659887

Group type: EXPERIMENTAL
Intervention: Aleglitazar
Number of subjects: 4303

Group type: EXPERIMENTAL
Intervention: Change in HOMA-IR on study treatment
Number of subjects: 4303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4303
Study: 27598803

Group type: EXPERIMENTAL
Intervention: High-dose external beam radiation therapy (EBRT) up to 80 Gy plus androgen deprivation therapy (ADT) for 2 to 3 years
Number of subjects: 69
Study: 24670328

Group type: EXPERIMENTAL
Intervention: 200g beetroot-enriched bread (1.1 mmol nitrate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control bread (no beetroot; 0.01 mmol nitrate)
Number of subjects: 14
Study: 22939852

Group type: EXPERIMENTAL
Intervention: Saphenous vein
Number of subjects: 224

Group type: COMPARATOR
Intervention: Right internal thoracic artery
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 224
Study: 20230451

Group type: EXPERIMENTAL
Intervention: Essential oxygen oil (OxyRub)
Number of subjects: 505
Study: 18602921

Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte apheresis (n = 112)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Sham apheresis (n = 56)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Granulocyte/monocyte apheresis
Number of subjects: 168

Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 168
Study: 15798459

Group type: EXPERIMENTAL
Intervention: Complete clamping (CC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Selective clamping (SC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study: 14564429

Group type: EXPERIMENTAL
Intervention: Desmopressin nasal spray (test preparation)
Number of subjects: 32
Study: 10702965

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study: 8773862

Group type: EXPERIMENTAL
Intervention: Isoflurane at MAC 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isoflurane at MAC 1.5
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (preoperative measurements)
Number of subjects: 10
Study: 1831987

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daunorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICRF-187
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idarubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New anthracycline analogs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally active anthracyclines
Number of subjects: 0
Study: 6641534

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms HBs antigen, 3 doses at 0, 1, 6 months)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (40 micrograms HBs antigen, 3 doses at 0, 1, 6 months)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (40 micrograms HBs antigen, 5 doses at 0, 1, 2, 4, 6 months)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Passive-active vaccination (40 micrograms HBs antigen at 0, 1, 2, 4, 6 months + 3 ml hepatitis B immunoglobulin at 0, 2 months)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (3 doses at 0, 1, 6 months)
Number of subjects: 116
Study: 30151903

Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 41

Group type: COMPARATOR
Intervention: APAP + propylene glycol
Number of subjects: 41
Study: 29283401

Group type: EXPERIMENTAL
Intervention: Pictorial Dietary Assessment Tool (PDAT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: modified Comstock
Number of subjects: 132
Study: 26465403

Group type: EXPERIMENTAL
Intervention: Injection with saline
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Injection with anesthetic
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (non-injected)
Number of subjects: 70
Study: 24486242

Group type: EXPERIMENTAL
Intervention: Telephone‐based individual MI counseling plus SM skills group (SM+MI)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Telephone‐based individual educational counseling plus group education (education control)
Number of subjects: 143
Study: 23102084

Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin (1 g) during surgery
Number of subjects: 325

Group type: COMPARATOR
Intervention: Multiple-dose antimicrobial prophylaxis (5 doses every 12 hours postoperatively)
Number of subjects: 325
Study: 19445860

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (375 microg, once daily for 3 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 17431757

Group type: EXPERIMENTAL
Intervention: Air bubble migration post embryo transfer
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Horizontal position post embryo transfer
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ultrasound guided embryo placement
Number of subjects: 88
Study: 15463883

Group type: EXPERIMENTAL
Intervention: Nebulized colistin sulphate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nebulized colistin sulphomethate
Number of subjects: 9
Study: 11354303

Group type: EXPERIMENTAL
Intervention: Prosorba column treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham column apheresis
Number of subjects: 0
Study: 9753292

Group type: EXPERIMENTAL
Intervention: CL 316,243 (1,500 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7822563

Group type: EXPERIMENTAL
Intervention: Dysthymics
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Anhedonics
Number of subjects: 3

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 3
Study: 3041815

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus piperacillin
Number of subjects: 243

Group type: COMPARATOR
Intervention: Moxalactam plus piperacillin
Number of subjects: 243

Group type: COMPARATOR
Intervention: Ceftazidime plus piperacillin
Number of subjects: 243

Group type: COMPARATOR
Intervention: Imipenem alone
Number of subjects: 243

Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 243
Study: 31344188

Group type: EXPERIMENTAL
Intervention: Watsu therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional hydrotherapy
Number of subjects: 46
Study: 28747354

Group type: EXPERIMENTAL
Intervention: mentor training
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: peer mentoring
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: combined mentor training and peer mentoring
Number of subjects: 150

Group type: COMPARATOR
Intervention: control condition (usual practice of mentoring)
Number of subjects: 150
Study: 25590673

Group type: EXPERIMENTAL
Intervention: Chlorella vulgaris supplement for 2 weeks
Number of subjects: 6
Study: 23435765

Group type: EXPERIMENTAL
Intervention: VA healthcare use among PTSD-positive women veterans
Number of subjects: 3611

Group type: EXPERIMENTAL
Intervention: Mental healthcare (MHC) service use among PTSD-positive women veterans
Number of subjects: 3611

Group type: EXPERIMENTAL
Intervention: MHC service use among VA-users
Number of subjects: 3611

Group type: EXPERIMENTAL
Intervention: MHC service use among VA-nonusers
Number of subjects: 3611

Group type: EXPERIMENTAL
Intervention: Predictors of MHC use among PTSD-positive women veterans
Number of subjects: 3611

Group type: EXPERIMENTAL
Intervention: Predictors of nonuse of MHC among PTSD-positive women veterans
Number of subjects: 3611

Group type: EXPERIMENTAL
Intervention: Overall PTSD prevalence in women veterans
Number of subjects: 3611
Study: 22001994

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.7 mg free base, 3 times a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropinirole (12 mg, once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa/Carbidopa (100/25 mg, 3 times a day)
Number of subjects: 0
Study: 17631898

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 2890

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 2890
Study: 16586360

Group type: EXPERIMENTAL
Intervention: 9-valent conjugate pneumococcal vaccine
Number of subjects: 2715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2715
Study: 14604310

Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Open tracheostomy (OT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Both PDT and OT
Number of subjects: 83
Study: 10664832

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control mix of essential amino acids
Number of subjects: 22
Study: 8844631

Group type: EXPERIMENTAL
Intervention: Continuous oral conjugated equine estrogen 0.625 mg daily
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Continuous transdermal estradiol-17 beta 50 mcg twice weekly
Number of subjects: 74
Study: 1324807

Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Number of subjects: 0
Study: 6523202

Group type: EXPERIMENTAL
Intervention: Vibratory massage of the uterus
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (no vibromassage)
Number of subjects: 303
Study: 2868973

Group type: EXPERIMENTAL
Intervention: 100 micrograms somatostatin analogue
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200 micrograms somatostatin analogue
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 6
Study: 31307674

Group type: EXPERIMENTAL
Intervention: PAM-sutured group
Number of subjects: 91

Group type: COMPARATOR
Intervention: PAM-non-sutured group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 29278961

Group type: EXPERIMENTAL
Intervention: Abobotulinumtoxin A (ABO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Onabotulinumtoxin A (ONA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both ABO and ONA
Number of subjects: 40
Study: 26685773

Group type: EXPERIMENTAL
Intervention: Risk prediction model for physical functioning
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Risk prediction model for psychological functioning
Number of subjects: 489
Study: 24964294

Group type: EXPERIMENTAL
Intervention: Facebook intervention with health coach moderation and self-regulatory techniques
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Facebook posts (polls and photos)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Overall engagement over time
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Passive engagement
Number of subjects: 404
Study: 23817989

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic medications
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional antipsychotic medications
Number of subjects: 108
Study: 23451547

Group type: EXPERIMENTAL
Intervention: Single take home dose of infant nevirapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (no changes made)
Number of subjects: 0
Study: 19142390

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch - Krieger-Kunz Method
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mock technique (control)
Number of subjects: 42
Study: 16368848

Group type: EXPERIMENTAL
Intervention: Monitoring group: tracheal intubation at maximum block based on monitoring after atracurium 0.5 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2‐min group: tracheal intubation 2 min after injection of atracurium 0.5 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2‐min group
Number of subjects: 60
Study: 12839406

Group type: EXPERIMENTAL
Intervention: ID type III (n = 39)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: DJD group (n = 18)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: ID type I (n = 35)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 118
Study: 10376236

Group type: EXPERIMENTAL
Intervention: Clonazepam (1-4 mg/d, flexible dose)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9032843

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery
Number of subjects: 0
Study: 1794360

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg/day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 65
Study: 6228936

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31777547

Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) + Levetiracetam (LEV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sodium valproate (SV)
Number of subjects: 120
Study: 29744754

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment for seven sessions at 2-week intervals
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pulsed dye laser treatment for three sessions at 6-week intervals
Number of subjects: 20
Study: 27473749

Group type: EXPERIMENTAL
Intervention: Combined magneto-auriculotherapy (MAT) plus laser auriculotherapy (LAT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Magneto-auriculotherapy (MAT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Laser auriculotherapy (LAT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 43
Study: 25321188

Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 7 days
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 28 days
Number of subjects: 501
Study: 22978414

Group type: EXPERIMENTAL
Intervention: PNPLA3 I148M allele in HCV genotype 2 infected patients
Number of subjects: 382

Group type: COMPARATOR
Intervention: PNPLA3 I148M allele in HCV genotype 3 infected patients
Number of subjects: 382
Study: 20520636

Group type: EXPERIMENTAL
Intervention: Presence of IgH translocations (especially t(14;16))
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: FLC estimates
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Combination of abnormal FLC estimate and/or presence of high-risk IgH translocation
Number of subjects: 314
Study: 18442352

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger ST users and those with a history of depression
Number of subjects: 0
Study: 15990911

Group type: EXPERIMENTAL
Intervention: Telephone social support and education for 13 months
Number of subjects: 197

Group type: COMPARATOR
Intervention: Mailed educational resource kit
Number of subjects: 197
Study: 11600561

Group type: EXPERIMENTAL
Intervention: Budesonide (800 microg/d for 2 months, then 400 microg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg/d for 2 months, then 200 microg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cromone treatment (control group)
Number of subjects: 60
Study: 9875641

Group type: EXPERIMENTAL
Intervention: Anti-HCV positive patients
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Non-cirrhotic patients
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Anti-HCV positivity
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: HBsAg positivity
Number of subjects: 1148
Study: 7991907

Group type: EXPERIMENTAL
Intervention: Thoracic epidural block with bupivacaine (8 ml of 0.5% bupivacaine with adrenalin 1:200.000) administered 30 min before surgery and combined anesthesia with isoflurane.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional balanced anesthesia with isoflurane and endovenous fentanyl (2.5 micrograms/kg) and saline solution administered through an epidural catheter.
Number of subjects: 30
Study: 2575367

Group type: EXPERIMENTAL
Intervention: Cicletanine (50 to 100 mg/day) combined with beta-blockers
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Cicletanine (50 to 100 mg/day) combined with calcium inhibitors
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Cicletanine (50 to 100 mg/day) combined with angiotensin-converting enzyme inhibitors
Number of subjects: 1668

Group type: EXPERIMENTAL
Intervention: Cicletanine (50 to 100 mg/day)
Number of subjects: 1668
Study: 182348

Group type: EXPERIMENTAL
Intervention: Estrogens (Premarin, Provera, diethylstilbestrol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or Provera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments combined (Stage III and IV patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated pretreatment fibrinogen levels
Number of subjects: 0
Study: 31377692

Group type: EXPERIMENTAL
Intervention: REACH‐HF intervention (self‐help manual for patients with HFrEF and caregivers facilitated over 12 weeks by trained healthcare professionals)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Qualitative data from intervention participants and caregivers
Number of subjects: 160
Study: 30550135

Group type: EXPERIMENTAL
Intervention: Intratympanic injection of dexamethasone 0.5 ml
Number of subjects: 48

Group type: COMPARATOR
Intervention: Postauricular injection of methylprednisolone 40 mg
Number of subjects: 48
Study: 26499352

Group type: EXPERIMENTAL
Intervention: Probiotics group A (1 g Clostridium butyricum MIYAIRI twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Probiotics group B (Bifidobacterium longum BB536 twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Digestive enzymes group (Aczym, containing 100 mg takadiastase N, 20 mg cellulase AP, 50 mg lipase MY, and 100 mg pancreatin, twice daily)
Number of subjects: 60
Study: 24837889

Group type: EXPERIMENTAL
Intervention: OAMCGT plus IMRT (arm 1; n=21)
Number of subjects: 44

Group type: COMPARATOR
Intervention: IMRT only (arm 2; n=23)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 44